Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Net Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Net Margin for 4 consecutive years, with 2419.05% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin fell 85613.0% to 2419.05% in Q3 2025 year-over-year; TTM through Sep 2025 was 2665.05%, a 50143.0% decrease, with the full-year FY2024 number at 2310.27%, down 58357.0% from a year prior.
  • Net Margin was 2419.05% for Q3 2025 at Orchestra BioMed Holdings, down from 2316.15% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 69.94% in Q3 2022 to a low of 6385.38% in Q4 2024.
  • A 4-year average of 2195.6% and a median of 2051.03% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -387272bps in 2023, then surged 168505bps in 2024.
  • Orchestra BioMed Holdings' Net Margin stood at 891.02% in 2022, then crashed by -435bps to 4763.74% in 2023, then tumbled by -34bps to 6385.38% in 2024, then skyrocketed by 62bps to 2419.05% in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Net Margin are 2419.05% (Q3 2025), 2316.15% (Q2 2025), and 2160.71% (Q1 2025).